DeCure's autonomous AMR AI scientist is researching a drug-repurposing hypothesis for hepatitis D virus infection — screening already-approved drugs against its 10-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHepatitis D virus infection maps to a 10-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hepatitis d virus infection is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
farnesyltransferase, CAAX box, subunit alpha (FNTA) — FNTA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet fardrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2H6F · 1.5 Å · ligand FARNESYL (FAR). Experimental structure, not a prediction.
What the evidence adds up to
Hepatitis D virus (HDV) infection is consistently described as the most severe form of chronic viral hepatitis, leading to rapid progression to liver cirrhosis and hepatocellular carcinoma. One review states that chronic HDV infection leads to cirrhosis and liver cancer in approximately 70% of patients within 15 years of infection, affecting over 12 million people worldwide. HDV is a defective RNA virus that depends on hepatitis B virus envelope proteins for packaging its ribonucleoprotein complex. The virus encodes only one protein, the hepatitis delta antigen, which exists in two forms. Many steps of the HDV life cycle remain enigmatic, and cellular factors involved in viral replication, morphogenesis, and pathogenesis are still being characterised.
Despite the discovery of HDV almost 50 years ago, progress in diagnosis and treatment has been scarce until recent years. The approval of bulevirtide is noted as having shed some light for patients with chronic hepatitis D, though important gaps regarding its use in therapy remain. One 2021 paper states there are no effective antiviral drugs. A 2022 review emphasises that little attention has been paid to this pathogen from both scientific and public communities, and that effectively combating hepatitis D requires advanced scientific knowledge and joint efforts from multiple stakeholders.
Research into new therapeutic strategies is ongoing. One study describes exosomes derived from mature dendritic cells loaded with ubiquitinated hepatitis D antigen, which induced a potent specific cellular immune response and inhibited HDV replication in an in vivo model. The authors suggest this may provide a new therapeutic strategy to eradicate HDV in the future. Another review summarises recent progress in antiviral strategies targeting cellular structures involved in the HDV life cycle.
What is still missing are large-scale, well-funded clinical trials that can confirm the efficacy of emerging treatments like bulevirtide and experimental immunotherapies in diverse patient populations. The field lacks a clear understanding of how to stratify patients for different treatment approaches, and the basic virology of HDV—including the role of cellular factors and immune system interplay in both viral control and liver disease pathogenesis—remains incompletely defined.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Viruses · 2023 · 16 citations · open access
Cellular Factors Involved in the Hepatitis D Virus Life Cycle
AbstractHepatitis D virus (HDV) is a defective RNA virus with a negative-strand RNA genome encompassing less than 1700 nucleotides. The HDV genome encodes only for one protein, the hepatitis delta antigen (HDAg), which exists in two forms acting as nucleoproteins. HDV depends on the envelope proteins of the hepatitis B virus as a helper virus for packaging its ribonucleoprotein complex (RNP). HDV is considered the causative agent for the most severe form of viral hepatitis leading to liver fibrosis/cirrhosis and hepatocellular carcinoma. Many steps of the life cycle of HDV are still enigmatic. This review gives an overview of the complete life cycle of HDV and identifies gaps in knowledge. The focus is on the description of cellular factors being involved in the life cycle of HDV and the deregulation of cellular pathways by HDV with respect to their relevance for viral replication, morphogenesis and HDV-associated pathogenesis. Moreover, recent progress in antiviral strategies targeting cellular structures is summarized in this article.
AbstractHepatitis D virus (HDV) infection leads to the most severe form of chronic viral hepatitis and requires the attention of a liver specialist. In this review, I will recapitulate recent advances in the management of HDV, present background information on HDV infection as well as current chronic hepatitis D treatment, briefly examine the HDV life cycle and discuss new management strategies.
United European Gastroenterology Journal · 2023 · 12 citations · open access
Management of chronic HBV‐HDV patients chronic HBV‐HDV infection: A review on new management options
AbstractHepatitis D virus was first described by Mario Rizzeto in 1977, and it is considered chronic viral hepatitis with the poorest prognosis. Despite its discovery almost 50 years ago, progress in its diagnosis and treatment has been scarce until recent years. The approval of bulevirtide has shed some light for patients with Chronic Hepatitis D, although important gaps regarding its use in therapy as well as about the epidemiology and diagnosis of the disease need to be addressed.
Microbiology Spectrum · 2021 · 8 citations · open access
Ubiquitinated Hepatitis D Antigen-Loaded Microvesicles Induce a Potent Specific Cellular Immune Response to Inhibit HDV Replication in Vivo
AbstractHepatitis D is the most severe viral hepatitis with accelerating the process of liver cirrhosis and increasing the risk of hepatocellular carcinoma. However, there are no effective antiviral drugs. Exosomes derived from mature dendritic cells are used not only as immunomodulators, but also as biological carriers to deliver antigens to induce robust immune response. Based on these properties, exosomes could be used as a biological immunotherapy by enhancing adaptive immune response to inhibit hepatitis D virus replication. Our research may provide a new therapeutic strategy to eradicate HDV in the future.
Chinese Medical Journal · 2022 · 7 citations · open access
Hepatitis D: advances and challenges
AbstractABSTRACT: Hepatitis D virus (HDV) infection causes the most severe form of viral hepatitis with rapid progression to cirrhosis, hepatic decompensation, and hepatocellular carcinoma. Although discovered > 40 years ago, little attention has been paid to this pathogen from both scientific and public communities. However, effectively combating hepatitis D requires advanced scientific knowledge and joint efforts from multi-stakeholders. In this review, we emphasized the recent advances in HDV virology, epidemiology, clinical feature, treatment, and prevention. We not only highlighted the remaining challenges but also the opportunities that can move the field forward.
Liver International · 2022 · 5 citations · open access
Immunology of hepatitis D virus infection: General concepts and present evidence
AbstractInfection with the hepatitis D virus induces the most severe form of chronic viral hepatitis, affecting over 12 million people worldwide. Chronic HDV infection leads to rapid development of liver cirrhosis and hepatocellular carcinoma in ~70% of patients within 15 years of infection. Recent evidence suggests that an interplay of different components of the immune system are contributing to viral control and may even be implicated in liver disease pathogenesis. This review will describe general concepts of antiviral immune response and elicit the present evidence concerning the interplay of the hepatitis D virus with the immune system.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
